Naltrexone does not prevent the weight gain and hyperphagia induced by the antipsychotic drug sulpiride in rats.
Few pharmacological tools are currently available to counteract the excessive body weight gain often observed during prolonged administration of antipsychotic drugs. Most antipsychotic drugs block dopamine receptors, and both the brain dopaminergic and opioid systems appear to be involved in initiation and maintenance of feeding behavior, respectively. We evaluated whether the opioid antagonist naltrexone (NAL, 0.5-16 mg/kg/ip for 21 days) (a) affects body weight and food intake in gonadally-intact and drug-free female rats, (b) prevents obesity, hyperphagia, hyperprolactinemia and vaginal cycle disruption induced by long-term administration of the antipsychotic drug sulpiride (SUL, 20 mg/kg/ip for 21 days), or (c) reverses the acute hyperphagia induced by SUL (15 microg bilaterally), when directly applied in the perifornical lateral hypothalamus (PFLH). In drug-free rats, only NAL doses above 4 mg/kg, significantly decreased weight gain and food intake. Even though NAL (1 and 8 mg/kg) significantly attenuated SUL-induced hyperphagia and hyperprolactinemia, it did not reverse at any dose the weight gain and permanent diestrous induced by SUL. In addition, local NAL did not prevent the hyperphagia and polidypsia observed after acute intrahypothalamic SUL. Unexpectedly, the cumulative and 24 h food intake in SUL-treated rats was significantly increased by NAL. Collectively, these results do not support a role for endogenous opiates in the neural and endocrine mechanisms involved in weight gain during prolonged antipsychotic drug administration in rats.
Baptista
T
T
Laboratory of Behavioral Physiology, School of Medicine, University of Los Andes, Mérida, Venezuela.
Lacruz
A
A
Acosta
A
A
Colasante
C
C
de Quijada
M
M
de Mendoza
S
S
Mendoza
J M
JM
Hernández
L
L
D000818:Animals; D014150:Antipsychotic Agents / Q000009:adverse effects*; D004031:Diestrus / Q000187:drug effects; D004435:Eating / Q000187:drug effects; D005260:Female; D006963:Hyperphagia / Q000139:chemically induced* / Q000517:prevention & control; D009271:Naltrexone / Q000494:pharmacology* / Q000627:therapeutic use; D009292:Narcotic Antagonists / Q000494:pharmacology* / Q000627:therapeutic use; D009765:Obesity / Q000139:chemically induced* / Q000517:prevention & control; D051381:Rats; D017208:Rats, Wistar; D013469:Sulpiride / Q000009:adverse effects*; D015430:Weight Gain / Q000187:drug effects
D014150:Antipsychotic Agents; D009292:Narcotic Antagonists; D009271:Naltrexone; D013469:Sulpiride